Cardium Therapeutics, Inc. (CRXM: OTCQB) | Taxus Cardium

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
[b]Cardium Therapeutics, Inc. (CRXM: OTCQB) | Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments[/b]



Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments






Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments


PR Newswire






SAN DIEGO , April 15, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) today presented highlights of financial results fiscal year ended December 31, 2013, and other recent developments.



Taxus Cardium Presents Year-End 2013 Financial Results And Recent Developments

Focus on Gene Therapy and Regenerative Medicine Biologics



The Company recently announced that the U.S.-based Cardium Therapeutics operations will be primarily focused on the clinical and commercial development of its Generx ® and Excellagen ® advanced regenerative medicine therapeutics:



Generx ® (alferminogene tadenovec, Ad5FGF-4) is a Phase 3 angiogenic gene therapy for the potential treatment of patients with Cardiac Microvascular Insufficiency or CMI due to advanced coronary artery disease. CMI is a principal cause of Coronary Microvascular Dysfunction (CMD), a well-recognized clinical condition characterized by functional and structural abnormalities of the microvasculature (smaller blood vessels of the heart), which leads to myocardial ischemia and angina pectoris in the absence of large artery/obstructive disease. CMD, which is also sometimes referred to as microvascular angina, frequently cannot be addressed using traditional surgical approaches such as coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI, i.e. angioplasty and stents). In particular, many patients (1) have coronary artery disease that is not limited or localized to large vessels, (2) continue to experience angina after CABG or PCI, and/or (3) are not suitable candidates for surgical interventions.



Generx represents a new class of therapeutic designed to address a large and unmet medical need among patients with heart disease. It is estimated that 12% of patients with obstructive coronary artery disease continue to experience angina because their underlying medical condition is not fully addressed or cannot be resolved by chronic drugs or surgical/mechanical interventions.  In addition, a recent meta-analysis reported that approximately 20% of patients who have a coronary angiography due to ongoing angina do not have obvious large vessel disease, a condition generally referred to as Cardiac Syndrome X, many of whom are presumed to have coronary disease that is diffuse and/or affects smaller vessels within the heart that are not reachable through surgical intervention. Generx is designed to be a one-time non-surgical treatment that may help many of such patients by directly addressing their underlying microvascular angina, as well as providing a non-surgical option for patients in whom coronary intervention is either contraindicated or not desirable.



Excellagen ® is an FDA-cleared, pharmaceutically-formulated acellular biological modulator that has been engineered to activate and promote wound healing through the growth of granulation tissue in chronic non-healing diabetic foot,  pressure and venous ulcers, as well as other dermal wounds (including traumatic and surgical wounds).  We believe that Excellagen is a cost-effective, easy to use professional product that has now been classified for reimbursement purposes by the U.S. Centers for Medicare and Medicaid Services as a unique "skin substitute"- a designation which is consistent with other forms of skin substitutes including living skin equivalents. Excellagen is expected to have additional potential applications for tissue regeneration and implant scaffolding using stem cells and other biologics.  To learn more about the Company's new regenerative medicine focus visit www.cardiumthx.com .



Corporate Development Activities



During 2013 and recently, Cardium initiated a number of important corporate development activities, including a strategic collaboration and funding agreement with Shanxi Taxus Pharmaceuticals Co., Ltd. that is designed to support the international commercial development of  Generx and Excellagen and to explore the development of these technologies and business opportunities in the People's Republic of China.  To reflect the inclusion of these new opportunities and funding support, Cardium Therapeutics changed its name to Taxus Cardium Pharmaceuticals Group.  In 2013, stockholders approved an institutional funding and a reverse stock split.  In addition, reflecting the Company's strategic focus on regenerative medicine biologics, the Company exchanged its To Go Brands ® nutraceutical and health sciences operating business for an equity interest in Healthy Brands Collective, a business unit of Cell-nique Corporation, a growing private company acquiring new and innovative health food products, with plans to complete an initial public offering at an appropriate time, which will serve to monetize the Company's equity position.  In addition, the Company has completed its first strategic partnering for LifeAgain, an advanced medical data analytics business, and plans to support this non-core investment through independent external funding sources.  Based on these transactions and other actions, the Company has significantly reduced its overall operating cost structure as it primarily focuses on the technology and clinical development of its innovative gene therapy and regenerative medicine biologics.    



Generx ® Angiogenic Gene Therapy Product Candidate



The Generx product candidate (alferminogene tadenovec, Ad5FGF-4) is an angiogenic gene therapy that is being developed as a pioneering treatment for Cardiac Microvascular Insufficiency or CMI in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to advanced coronary artery disease (CAD). Patients with CMI are no longer responsive to medical therapy, and are not considered suitable candidates for traditional revascularization procedures, either because of their medical condition or because they continue to have persistent exertional angina despite having satisfactory large coronary artery blood flow based on an angiographic evaluation.  Coronary Microvascular Dysfunction (CMD) is a well-recognized clinical condition that describes functional and structural abnormalities of the microvasculature that can lead to myocardial ischemia in the absence of large artery/obstructive disease (microvascular angina), and therefore encompasses CMI. Traditional surgical approaches such as coronary artery bypass graft (CABG) and percutaneous coronary intervention (PCI) are designed to address blockages in the large vessels of the heart that can be reached using such methods. However, many patients (1) have CAD that is not limited to large vessels, (2) continue to experience angina after CABG or PCI, and/or (3) are not suitable candidates for surgical interventions. It is believed that patients with CMI have insufficient microvascular blood flow (i.e. within medium to smaller blood vessels) during exertion due to their advanced coronary artery disease and may benefit from Generx therapy to biologically enhance cardiac perfusion by the promotion of collateral vessel formation. Company researchers believe that biologically enhanced perfusion offers the opportunity to reduce angina attacks and improve quality of life for patients with advanced CAD, and large-scale studies and clinical reviews have now shown that increased perfusion can be cardio-protective and improve outcomes following a major adverse cardiac event.



Following a one-time intracoronary catheter-based delivery by an interventional cardiologist in a routine out-patient procedure (that is very similar to an angiography procedure), Generx is designed to drive the localized, short-term cellular expression of FGF-4 protein, which in turn stimulates the release and action of other key growth factors to orchestrate and promote the growth of cardiac microvascular circulation (functional collateral network) in ischemic cardiac tissue through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). An independent long-term prospective study has demonstrated the importance of collateral circulation beyond simply the relief of angina and provided further support of the potential for long term benefits from Generx therapy. Upon completion of the ongoing ASPIRE international clinical study, Generx will have been the subject of five randomized and controlled multi-center clinical studies involving approximately 750 patients at over 100 medical centers in the United States , Canada , Western Europe , South America and the Russian Federation . The combined clinical study data will represent one of the largest clinical and regulatory gene therapy dossiers in the world, and suggests that Generx appears to be safe and well tolerated, and is potentially capable of improving myocardial perfusion in patients with myocardial ischemia due to advanced coronary artery disease.  To learn more about the Generx angiogenic gene therapy product candidate visit http://www.cardiumthx.com/generx.html .



Excellagen ® FDA-Cleared Wound Care Product



Excellagen is a homogenate of purified bovine dermal collagen (Type I) in its native 3-dimensional fibrillar configuration, physiologically formulated as a sterile professional-use syringe, capable of providing a structural scaffold for cellular infiltration and wound granulation. Excellagen can activate platelets, triggering release of essential growth factors and is believed to function as an acellular biological modulator to activate the wound healing process and significantly accelerate the growth of granulation tissue. Excellagen's FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/graft, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds. 



Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Excellagen's unique fibrillar collagen formulation is topically applied through easy-to-control, pre-filled sterile syringes and is designed for application at one-week intervals.  Effective January 1, 2014 , the Centers for Medicare and Medicaid Services (CMS) assigned Excellagen a unique, product-specific Q code (Q4149), classifying Excellagen as a skin substitute, indicated for the treatment of hard to heal wounds such as diabetic foot ulcers and pressure ulcers as well as other dermal wounds. Consistent with the Company's long-term business strategy, as previously reported, we not plan to establish an internal marketing and sales force for commercialization of Excellagen, but rather to fully credentialize Excellagen in preparation for the completion of strategic partnerings within various vertical channel market opportunities or asset monetization.  The Company has continued to pursue a CE mark certification for Excellagen, has fully responded to all information requested by the notified body, and looks forward to completing this process.  For more information, visit www.excellagen.com . 



In addition to its application for the treatment of chronic non-healing dermal wounds, Excellagen's pharmaceutically formulated collagen has been engineered to serve as a biologics delivery platform, enabling multiple device, tissue scaffolding and therapeutic product extensions for tissue regeneration based on stem cells, biologics, peptides and small molecule drugs. It is believed that the application of Excellagen as a mesenchymal stem cell delivery platform can facilitate wound healing, which is the subject of ongoing preclinical studies.



Financial Report for 2013



After adjusting for the sale of the Company's To Go Brands® operating business, revenues for the year ended December 31, 2013 totaled $109,000 , compared to revenues of $59,000 for the year ended December 31 , 2012.  The Company reported a net loss from continuing operations totaling $6.9 million for the year ended 2013, compared to the prior year of $8.3 million , representing a reduction of $1.4 million , or 17%. A net loss from discontinued operations totaled $2.0 million was reported in 2013, reflecting the operating losses of the To Go Brands business during the period we owned it, and a $1.1 million write-off of technology licenses relating to the nutraceutical product line acquired with Cardium stock in 2010 and 2011.  The net loss for 2013 totaled $8.9 million ( $1.33 per share), compared to a net loss of $8.3 million ( $1.41 per share) in 2012.   For the year ended December 31, 2013 , research and development expenses totaled $2.0 million , and selling, general and administrative expenses were $4.9 million , compared to $2.6 million and $5.7 million , respectively, for 2012.  The decreases in selling, general and administrative expenses, and research and development expenses, were primarily due to reductions in research, testing and marketing activities for Excellagen and overall reductions in corporate overhead, staffing and salary reductions.  Cardium ended the 2013 year with a working capital deficit of $1.1 million , compared to working capital from continuing operations of $3.5 million in 2012.  After adjusting for the stockholder approved reverse stock split, the total shares of Common Stock outstanding at December 31, 2013 were 8.8 million, and there were an additional 1.5 million shares of Common Stock issuable upon the conversion of Series A Preferred Stock into Common Stock as of December 31, 2013 , for approximately 10.3 million total shares.



The Company also indicated that similar to 2012, the audit opinion accompanying its consolidated financial statements for the year ended December 31, 2013 , will contain a going concern qualification from its independent registered public accounting firm, Marcum LLP.  Consistent with its business strategy and as outlined in this press release, Cardium plans to raise additional funds through the sale of additional equity to Shanxi Taxus or other investors, the strategic sale or monetization of operating units, entering into strategic licensing agreements, and/or other financing transactions.



Forward-Looking Statements



Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from expectations. For example, there can be no assurance that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or in actual use; that new clinical studies will be successful or will lead to approvals or clearances from health regulatory authorities, or that approvals in one jurisdiction will help to support studies or approvals elsewhere; that the company can attract suitable commercialization partners for our products or that we or partners can successfully commercialize them; that our product or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive or blocked by third party proprietary rights or other means; that the products and product candidates referred to in this report or in our other reports will be successfully commercialized and their use reimbursed, or will enhance our market value; that new product opportunities or commercialization efforts will be successfully established; that third parties on whom we depend will perform as anticipated; that we can raise sufficient capital from partnering, monetization or other fundraising transactions to maintain our stock exchange listing or adequately fund ongoing operations; or that we will not be adversely affected by these or other risks and uncertainties that could impact our operations, business or other matters, as described in more detail in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.



Copyright 2014 Cardium Therapeutics, Inc.  All rights reserved.
For Terms of Use Privacy Policy, please visit www.cardiumthx.com .



Cardium Therapeutics ® , Generx ® , Cardionovo ® , Tissue Repair™, Excellagen ® , Excellarate™, Genedexa™, and LifeAgain™, are trademarks of Cardium Therapeutics, Inc., Tissue Repair Company or LifeAgain Insurance Solutions Inc. Other trademarks belong to their respective owners.












































































































































































































Taxus Cardium Pharmaceuticals Group, Inc.



Selected Condensed Consolidated Results of Operations










The year ended December 31,







2013




2012











Product sales





$     109,200




$          59,409




Cost of goods sold





(69,160)




(54,151)




Gross profit





40,040




5,258




   Operating expenses









Research and development





(2,037,370)




(2,581,094)




Selling, general and administrative





(4,908,919)




(5,717,985)




Loss from operations





(6,906,249)




(8,293,821)




Interest income (expense), net





(554)




2,550




Change in fair value of derivative liabilities





---




64,157




Net loss from continuing operations





$   (6,906,803)




$ (8,227,114)




Net Loss from discontinued operations





(2,007,490)




(96,196)




Net Loss





$   (8,914,293)




$   (8,323,310)




Deemed dividend on preferred stock





$    (405,872)




$              ---




Net loss applicable to common stockholders





$   (9,320,165)




$    (8,323,310)




Net loss per common  share – basic and diluted









Net loss from continued operations





$   (1.04)




$   (1.39)




Net loss from discontinued operations





(0.29)




(0.02)




Net loss per share – basic and diluted





$      (1.33)




$   (1.41)











Weighted average common shares outstanding  – basic and diluted





 



6,995,676




 



5,922,717












 











































































































Selected Condensed Consolidated Balance Sheet Data






December 31, 



2013




December 31,



2012



Cash and cash equivalents




$          22,489




$         2,182,118



Accounts receivable




          __




22,320



Inventory




159,831




682,094



Prepaid expenses and other current



   assets




 



309,200




 



403,705



Property and equipment, net




30,196




52,115








Other long-term assets




2,264,661




1,809,126



Assets of discontinued operations




---




2,657,400



Total assets




$     2,786,377




$         7,808,878










Accounts payable and accrued liabilities




$     1,601,286




$             801,008



Liabilities of discontinued operations




---




642,080



Total liabilities




1,601,286




1,443,088



Stockholder's equity




1,185,091




6,365,790



Total liabilities and stockholder's equity




$     2,786,377




$         7,808,878



 



Taxus Cardium Pharmaceuticals Group Logo

Photo - http://photos.prnewswire.com/prnh/20140415/LA04094
Logo - http://photos.prnewswire.com/prnh/20140317/LA83695LOGO


SOURCE Taxus Cardium Pharmaceuticals Group Inc.






Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 489

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 775

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 106

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CommBank Yello Builds a Wider Moat Around Customers

Updated Category News Views 23

Nine million customers is not a pilot program; it is a crowded stadium, and CommBank has decided to hand everyone a reason to stay in their seats. Commonwealth Bank's expanded CommBank Yello program now lets eligible customers earn points across home loans, term deposits, cards and insurance, then redeem with well-known brands. That is a serious attempt to make a bank...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Global Voices: WAC conference speaker lineup

Updated Category News Views 322

Premier Speakers Set to Inspire at the World Affairs Conference Excitement continues to build for the upcoming World Affairs Conference (WAC), attracting attention from students and educators alike. This prestigious event promises a day filled with thought-provoking discussions and insights from renowned speakers, including Bill Weir, Keith Pelley, and Dr. James Orbinski....

Continue Reading
Transform Your Investment Journey With Westinghouse Air Brake

Updated Category News Views 166

Long-Term Growth of Westinghouse Air Brake Understanding the remarkable growth of Westinghouse Air Brake is essential for current and prospective investors. Over the elapsed two decades, this company has consistently outperformed the market, achieving an impressive annualized growth rate of 14.54%. Cumulative Return on Investment If one had invested $100 in Westinghouse...

Continue Reading
Revitalizing Healthcare: Bipartisan Efforts to Combat Sepsis

Updated Category News Views 179

Revitalizing Healthcare Efforts with the SEPSIS Act In a significant move to address one of the most critical health challenges facing the nation today, the SEPSIS Act has been reintroduced in the Senate. This bipartisan legislation aims to tackle the sepsis crisis—a pressing issue that affects countless families and places a heavy burden on healthcare resources. With a...

Continue Reading
Transforming Innovation: The Charles Huang Initiative in Glasgow

Updated Category News Views 256

Revitalizing Education and Innovation The Charles Huang Foundation (CHF) has announced a transformative project at the University of Strathclyde, aiming to bolster educational and entrepreneurial efforts through a £30 million investment. This funding will be pivotal in converting a former Student Union building on John Street into the Charles Huang Advanced Technology &...

Continue Reading
Ally Waste Chosen for Valet Trash Services by RangeWater Real Estate

Updated Category News Views 190

Ally Waste Partners with RangeWater Real Estate for Waste Solutions Ally Waste, a prominent provider of valet trash services and various onsite waste solutions for multifamily communities, has been selected as the preferred valet trash service provider for RangeWater Real Estate. This decision comes after a meticulous evaluation of potential service partners through a...

Continue Reading